Advocacy intelligence hub — real-time data for patient organizations
Centre Hospitalier Universitaire de Nice — PHASE2
TWi Biotechnology, Inc. — PHASE2, PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Browse all Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form news →